JP2018500896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500896A5 JP2018500896A5 JP2017530591A JP2017530591A JP2018500896A5 JP 2018500896 A5 JP2018500896 A5 JP 2018500896A5 JP 2017530591 A JP2017530591 A JP 2017530591A JP 2017530591 A JP2017530591 A JP 2017530591A JP 2018500896 A5 JP2018500896 A5 JP 2018500896A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- polypeptide
- gene
- human
- endogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000283984 Rodentia Species 0.000 claims description 134
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 108
- 102000048776 human CD274 Human genes 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 40
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 37
- 101150091609 CD274 gene Proteins 0.000 claims description 36
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 16
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000003834 intracellular effect Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 230000004614 tumor growth Effects 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 16
- 150000007523 nucleic acids Chemical group 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 17
- 108010074708 B7-H1 Antigen Proteins 0.000 description 17
- 108700024394 Exon Proteins 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000048362 human PDCD1 Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 1
- 101100407306 Mus musculus Cd274 gene Proteins 0.000 description 1
- 101001117316 Mus musculus Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 229940122862 PD-L1 agonist Drugs 0.000 description 1
- 229940123751 PD-L1 antagonist Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089549P | 2014-12-09 | 2014-12-09 | |
| US62/089,549 | 2014-12-09 | ||
| US201562106525P | 2015-01-22 | 2015-01-22 | |
| US62/106,525 | 2015-01-22 | ||
| PCT/US2015/064626 WO2016094481A1 (en) | 2014-12-09 | 2015-12-09 | Non-human animals having a humanized cluster of differentiation 274 gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168478A Division JP7145920B2 (ja) | 2014-12-09 | 2020-10-05 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018500896A JP2018500896A (ja) | 2018-01-18 |
| JP2018500896A5 true JP2018500896A5 (OSRAM) | 2019-01-24 |
Family
ID=55024286
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530591A Withdrawn JP2018500896A (ja) | 2014-12-09 | 2015-12-09 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
| JP2020168478A Active JP7145920B2 (ja) | 2014-12-09 | 2020-10-05 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
| JP2022148949A Active JP7488861B2 (ja) | 2014-12-09 | 2022-09-20 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168478A Active JP7145920B2 (ja) | 2014-12-09 | 2020-10-05 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
| JP2022148949A Active JP7488861B2 (ja) | 2014-12-09 | 2022-09-20 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9913461B2 (OSRAM) |
| EP (3) | EP3808775B1 (OSRAM) |
| JP (3) | JP2018500896A (OSRAM) |
| KR (2) | KR102457921B1 (OSRAM) |
| CN (2) | CN113412818B (OSRAM) |
| AU (3) | AU2015360667B2 (OSRAM) |
| BR (1) | BR112017011982A2 (OSRAM) |
| CA (1) | CA2968675C (OSRAM) |
| CY (1) | CY1123723T1 (OSRAM) |
| DK (2) | DK3230320T3 (OSRAM) |
| ES (2) | ES2982515T3 (OSRAM) |
| FI (1) | FI3808775T3 (OSRAM) |
| HR (2) | HRP20240855T1 (OSRAM) |
| HU (2) | HUE067123T2 (OSRAM) |
| IL (3) | IL282649B (OSRAM) |
| LT (2) | LT3808775T (OSRAM) |
| MX (1) | MX2017007636A (OSRAM) |
| NZ (2) | NZ770783A (OSRAM) |
| PL (1) | PL3808775T3 (OSRAM) |
| PT (2) | PT3230320T (OSRAM) |
| RS (2) | RS65664B1 (OSRAM) |
| RU (1) | RU2711729C2 (OSRAM) |
| SG (2) | SG10202100792XA (OSRAM) |
| SI (2) | SI3230320T1 (OSRAM) |
| SM (2) | SMT202100148T1 (OSRAM) |
| WO (1) | WO2016094481A1 (OSRAM) |
| ZA (1) | ZA201703263B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015360667B2 (en) * | 2014-12-09 | 2021-09-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| EP3376857B1 (en) | 2015-11-20 | 2021-02-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
| ES2908669T3 (es) | 2016-02-04 | 2022-05-03 | Regeneron Pharma | Animales no humanos que tienen un gen ANGPTL8 modificado genéticamente |
| PT3422845T (pt) | 2016-02-29 | 2021-08-26 | Regeneron Pharma | Roedores com um gene tmprss humanizado |
| DK3476865T5 (da) * | 2016-06-28 | 2024-09-09 | Biocytogen Pharmaceuticals Beijing Co Ltd | Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf |
| WO2018041118A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric pd-l1 |
| CN107815467B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| CN107815466B (zh) | 2016-08-31 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
| CN110234661B (zh) | 2016-12-01 | 2024-03-29 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的抗-pd-l1抗体 |
| CN109666701B (zh) * | 2017-10-13 | 2021-08-24 | 百奥赛图(北京)医药科技股份有限公司 | 一种pd-1基因修饰人源化动物模型的构建方法及其应用 |
| WO2019072241A1 (en) * | 2017-10-13 | 2019-04-18 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC |
| CN111655031B (zh) | 2017-11-30 | 2022-11-18 | 瑞泽恩制药公司 | 包含人源化trkb基因座的非人动物 |
| WO2019114768A1 (en) | 2017-12-12 | 2019-06-20 | Biocytogen Jiangsu Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e |
| IL314733A (en) | 2018-03-26 | 2024-10-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| US11589562B2 (en) | 2018-07-16 | 2023-02-28 | Regeneran Pharmaceuticals, Inc. | Mouse model of DITRA disease and uses thereof |
| CN110846321B (zh) * | 2018-08-21 | 2021-11-19 | 中国科学院动物研究所 | 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途 |
| WO2020081585A1 (en) * | 2018-10-15 | 2020-04-23 | The Brigham And Women's Hospital, Inc. | The long non-coding rna inca1 and homo sapiens heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) as therapeutic targets for immunotherapy |
| CN109452229B (zh) * | 2018-11-19 | 2021-10-22 | 百奥赛图(北京)医药科技股份有限公司 | 狗源化pd-1基因改造动物模型的制备方法及应用 |
| CN109979539B (zh) * | 2019-04-10 | 2020-10-02 | 电子科技大学 | 基因序列优化方法、装置及数据处理终端 |
| US20240130340A1 (en) * | 2021-02-19 | 2024-04-25 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric cd3 genes |
| CN112999368A (zh) * | 2021-04-09 | 2021-06-22 | 广东药康生物科技有限公司 | 人源化模型进行药效评价方法的建立 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US6485964B1 (en) * | 1995-03-20 | 2002-11-26 | Arris Pharmaceutical Corporation | Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor |
| GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US20020164600A1 (en) | 2000-06-28 | 2002-11-07 | Gordon Freeman | PD-L2 molecules: novel PD-1 ligands and uses therefor |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| DE10211088A1 (de) * | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| KR20050084317A (ko) * | 2002-12-16 | 2005-08-26 | 제넨테크, 인크. | 인간 ｃｄ２０ 및(또는) ｃｄ１６을 발현하는 트랜스제닉마우스 |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| AU2004304665B2 (en) | 2003-12-24 | 2009-03-12 | Novo Nordisk A/S | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR |
| ATE510020T1 (de) | 2003-12-24 | 2011-06-15 | G2 Inflammation Pty Ltd | Transgenes nichtmenschliches säugetier mit einem polynukleotid, das für human-c5ar oder humanisiertes c5ar codiert |
| HUE039237T2 (hu) | 2004-10-06 | 2018-12-28 | Mayo Found Medical Education & Res | B7-H1 és PD-1 vesesejt karcinoma kezelésében |
| DK1802193T3 (da) | 2004-10-19 | 2014-06-10 | Regeneron Pharma | Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US8216996B2 (en) | 2006-03-03 | 2012-07-10 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| MX340972B (es) | 2008-10-08 | 2016-08-02 | Intrexon Corp | Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas. |
| AU2009329365B2 (en) * | 2008-12-18 | 2016-01-14 | Roger Kingdon Craig | Non-human transgenic animals expressing humanised antibodies and use thereof |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| WO2011020014A1 (en) | 2009-08-14 | 2011-02-17 | Regeneron Pharmaceuticals, Inc. | Promoter-regulated differentiation-dependent self-deleting cassette |
| BR112012004387A2 (pt) * | 2009-08-28 | 2015-09-08 | Vlst Corp | anticorpos anticinas que se l igam a múltiplas quimiocinas cc. |
| ES2908587T3 (es) | 2009-10-06 | 2022-05-03 | Regeneron Pharma | Ratones modificados genéticamente e injerto |
| US20120263692A1 (en) | 2009-11-16 | 2012-10-18 | Bertone Alicia L | Engineered Xenogeneic Cells for Repair of Biological Tissue |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| SG10201408415PA (en) * | 2009-12-21 | 2015-01-29 | Regeneron Pharma | HUMANIZED FCγ R MICE |
| EP4385568A3 (en) * | 2010-04-06 | 2025-02-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of cd274/pd-l1 gene |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| EP2770822B9 (en) | 2011-10-28 | 2019-12-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
| BR112014008529A2 (pt) | 2011-10-28 | 2017-04-18 | Regeneron Pharma | il-6 humanizado e receptor de il-6 |
| DK2770821T3 (da) * | 2011-10-28 | 2017-11-27 | Regeneron Pharma | Genetisk modificerede major histocompatibility-kompleks-mus |
| US9644179B2 (en) | 2011-11-23 | 2017-05-09 | The Trustees Of The University Of Pennsylvania | Use of PDL1 expressing cells to convert T cells into regulatory T cells |
| LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
| ES2848052T3 (es) | 2012-08-03 | 2021-08-05 | Dana Farber Cancer Inst Inc | Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso |
| US20140047572A1 (en) * | 2012-08-13 | 2014-02-13 | University Of Rochester | Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury |
| JP6306588B2 (ja) * | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| RU2642319C2 (ru) | 2012-09-07 | 2018-01-24 | Йель Юниверсити | Генетически модифицированные, не принадлежащие к человеческому роду животные и способ их использования |
| PT3939423T (pt) | 2012-11-05 | 2024-05-29 | Regeneron Pharma | Animais não humanos geneticamente modificados e métodos de utilização dos mesmos |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| EP3561050B1 (en) | 2013-02-20 | 2021-12-08 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
| EP3543253B1 (en) | 2013-02-20 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| HRP20181866T1 (hr) | 2013-02-22 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| MX369747B (es) | 2013-04-16 | 2019-11-20 | Regeneron Pharma | Modificación dirigida del genoma de rata. |
| CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| WO2014197369A1 (en) | 2013-06-06 | 2014-12-11 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
| KR102407354B1 (ko) | 2013-09-23 | 2022-06-10 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물 |
| US20150143558A1 (en) | 2013-11-19 | 2015-05-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| DK3129400T3 (da) | 2014-04-08 | 2020-06-08 | Regeneron Pharma | Ikke-humane dyr med humaniserede Fc-gamma-receptorer |
| NO2785538T3 (OSRAM) | 2014-05-07 | 2018-08-04 | ||
| MX379268B (es) | 2014-05-19 | 2025-03-11 | Regeneron Pharma | Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. |
| SMT202000184T1 (it) | 2014-06-19 | 2020-05-08 | Regeneron Pharma | Animali non umani aventi un gene 1 della morte cellulare programmata umanizzato |
| EP3223605B9 (en) | 2014-11-24 | 2021-08-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized cd3 complex |
| HUE064960T2 (hu) | 2014-12-05 | 2024-04-28 | Regeneron Pharma | Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok |
| AU2015360667B2 (en) * | 2014-12-09 | 2021-09-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| EP3376857B1 (en) | 2015-11-20 | 2021-02-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized lymphocyte-activation gene 3 |
| WO2018041118A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric pd-l1 |
-
2015
- 2015-12-09 AU AU2015360667A patent/AU2015360667B2/en active Active
- 2015-12-09 EP EP20194168.9A patent/EP3808775B1/en active Active
- 2015-12-09 SI SI201531463T patent/SI3230320T1/sl unknown
- 2015-12-09 RS RS20240717A patent/RS65664B1/sr unknown
- 2015-12-09 JP JP2017530591A patent/JP2018500896A/ja not_active Withdrawn
- 2015-12-09 HR HRP20240855TT patent/HRP20240855T1/hr unknown
- 2015-12-09 RS RS20201547A patent/RS61218B1/sr unknown
- 2015-12-09 CN CN202110688677.9A patent/CN113412818B/zh active Active
- 2015-12-09 PL PL20194168.9T patent/PL3808775T3/pl unknown
- 2015-12-09 DK DK15816631.4T patent/DK3230320T3/da active
- 2015-12-09 NZ NZ770783A patent/NZ770783A/en unknown
- 2015-12-09 HU HUE20194168A patent/HUE067123T2/hu unknown
- 2015-12-09 SG SG10202100792XA patent/SG10202100792XA/en unknown
- 2015-12-09 BR BR112017011982A patent/BR112017011982A2/pt not_active Application Discontinuation
- 2015-12-09 PT PT158166314T patent/PT3230320T/pt unknown
- 2015-12-09 CA CA2968675A patent/CA2968675C/en active Active
- 2015-12-09 SM SM20210148T patent/SMT202100148T1/it unknown
- 2015-12-09 SI SI201532021T patent/SI3808775T1/sl unknown
- 2015-12-09 SG SG11201703931QA patent/SG11201703931QA/en unknown
- 2015-12-09 ES ES20194168T patent/ES2982515T3/es active Active
- 2015-12-09 US US14/963,402 patent/US9913461B2/en active Active
- 2015-12-09 HU HUE15816631A patent/HUE052606T2/hu unknown
- 2015-12-09 FI FIEP20194168.9T patent/FI3808775T3/fi active
- 2015-12-09 KR KR1020217033684A patent/KR102457921B1/ko active Active
- 2015-12-09 KR KR1020177016266A patent/KR102316842B1/ko active Active
- 2015-12-09 LT LTEP20194168.9T patent/LT3808775T/lt unknown
- 2015-12-09 EP EP15816631.4A patent/EP3230320B1/en active Active
- 2015-12-09 SM SM20240313T patent/SMT202400313T1/it unknown
- 2015-12-09 EP EP24167621.2A patent/EP4399969A3/en active Pending
- 2015-12-09 IL IL282649A patent/IL282649B/en unknown
- 2015-12-09 MX MX2017007636A patent/MX2017007636A/es unknown
- 2015-12-09 WO PCT/US2015/064626 patent/WO2016094481A1/en not_active Ceased
- 2015-12-09 NZ NZ731954A patent/NZ731954A/en unknown
- 2015-12-09 LT LTEP15816631.4T patent/LT3230320T/lt unknown
- 2015-12-09 RU RU2017123754A patent/RU2711729C2/ru active
- 2015-12-09 PT PT201941689T patent/PT3808775T/pt unknown
- 2015-12-09 HR HRP20202034TT patent/HRP20202034T1/hr unknown
- 2015-12-09 CN CN201580067025.6A patent/CN107257624B/zh active Active
- 2015-12-09 DK DK20194168.9T patent/DK3808775T3/da active
- 2015-12-09 ES ES15816631T patent/ES2841353T3/es active Active
-
2017
- 2017-05-11 ZA ZA2017/03263A patent/ZA201703263B/en unknown
- 2017-06-06 IL IL252695A patent/IL252695B/en active IP Right Grant
-
2018
- 2018-01-30 US US15/883,477 patent/US10881086B2/en active Active
-
2020
- 2020-07-06 IL IL275864A patent/IL275864B/en active IP Right Grant
- 2020-10-05 JP JP2020168478A patent/JP7145920B2/ja active Active
- 2020-12-03 US US17/110,868 patent/US12089575B2/en active Active
- 2020-12-23 CY CY20201101215T patent/CY1123723T1/el unknown
-
2021
- 2021-12-16 AU AU2021286369A patent/AU2021286369B2/en active Active
-
2022
- 2022-09-20 JP JP2022148949A patent/JP7488861B2/ja active Active
-
2024
- 2024-08-15 US US18/805,786 patent/US20240389563A1/en active Pending
-
2025
- 2025-06-24 AU AU2025204751A patent/AU2025204751A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500896A5 (OSRAM) | ||
| JP2017521060A5 (OSRAM) | ||
| RU2017123754A (ru) | Не относящиеся к человеку животные, имеющие гуманизированный ген кластера дифференцировки 274 | |
| JP2021094035A5 (OSRAM) | ||
| Tummala et al. | Poly (A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita | |
| KR102617691B1 (ko) | 인간화 분화 클러스터 47 유전자를 가진 비인간 동물 | |
| JP2018533963A5 (OSRAM) | ||
| Zemljic-Harpf et al. | Cardiac-myocyte-specific excision of the vinculin gene disrupts cellular junctions, causing sudden death or dilated cardiomyopathy | |
| RU2016149434A (ru) | Животные, отличные от человека, имеющие гуманизированный ген 1 запрограммированный гибели клеток | |
| JP2018500012A5 (OSRAM) | ||
| HRP20231121T1 (hr) | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale | |
| JP2015523863A5 (OSRAM) | ||
| JP2019505216A5 (OSRAM) | ||
| JP2018533963A (ja) | ヒト化されたｌｙｍｐｈｏｃｙｔｅ−ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物 | |
| EP3585445B1 (en) | Humanized model of kidney and liver disorders | |
| JP2011501652A5 (OSRAM) | ||
| IL314733A (en) | Humanized rodents for testing therapeutic agents | |
| JP2017213006A5 (OSRAM) | ||
| JP2019511918A5 (OSRAM) | ||
| JP2016519138A5 (OSRAM) | ||
| Wang et al. | Pno1 tissue-specific expression and its functions related to the immune responses and proteasome activities | |
| US20230413791A1 (en) | Non-human animals having a humanized clec9a gene | |
| US20220192165A1 (en) | Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene | |
| US20230146102A1 (en) | Monogenic or polygenic disease model organisms humanized with two or more genes | |
| Thompson | Gene expression evolution after duplication |